Comparative study of levofloxacin and ofloxacin in bacterial pneumonia by the double blind-method

Rinzo Soejima, Hiroshi Kawane, Niro Okimoto, Shigenori Umeki, Masaru Sumi, Sadao Tamada, Yoshifumi Kubota, Akira Saito, Kazuo Takebe, Tsuneharu Baba, Masakichi Motomiya, Akira Watanabe, Shigeo Takizawa, Tsukasa Yoshida, Ken ichi Takeuchi, Toshiharu Ito, Hiromi Kanayama, Kotaro Oizumi, Masataka Katsu, Masatoshi IshiiHiroshi Hirose, Norio Kikuchi, Hiroshi Tabeta, Hiroichi Tanimoto, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Takashi Inamatsu, Hiroshi Sakamoto, Makoto Kodaira, Makiko Fukayama, Hiroyuki Kobayashi, Junzaburo Kabe, Koichiro Kudo, Hitoshi Arioka, Masaru Koyama, Harumi Shishido, Masaaki Arakawa, Kouichi Wada, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Fumio Miki, Atsuhiko Sato, Masatoshi Iwata, Kingo Chida, Takafumi Suda, Takashi Hayakawa, Hirokazu Okano, Masahiko Okano, Masami Taniguchi, Masao Shibata, Katsutaka Torikai, Tatsuo Hamamoto, Fumiyuki Kuze, Kyosuke Ishihara, Takekuni Iwata, Kazukiyo Oida, Yoshio Taguchi, Yoshiaki Kori, Keisuke Tomii, Eiro Tsubura, Masaru Nakagawa, Min Kyong-yob, Mitsunori Sakatani, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michio Yamakido, Kenji Hasegawa, Naoki Yamaoka, Kohei Hara, Keizo Matsumoto, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Hozumi Yamada, Osamu Katoh, Kenya Hiura, Yosuke Aoki, Shigetaka Kuroki, Masaya Yamaguchi, Atsushi Saito, Yoshiteru Sigeno, Yuei Irabu, Hiroshi Fukuhara, Kenji Shiroma, Hisayuki Uehara, Nobuya Ogawa, Mitsuo Kaku, Kazuyuki Sugawara, Keizo Yamaguchi

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Levofloxacin (LVFX), a new oral quinolone antibacterial, was evaluated for its efficacy, safety and usefulness in patients with bacterial pneumonia by a randomized double-blind comparative study using ofloxacin (OFLX) as the control drug. The patients were given either LVFX (100mg t. i. d) or OFLX (200mg t. i. d) for 14 days, in principle. The results were as follows: 1) A total of 159 patients (LVFX 77, OFLX 82) were enrolled in the trial. The number of evaluable cases, assessed by the committee, was 140 for clinical efficacy (LVFX 68, OFLX 72), 158 for side effects (LVFX 76, OFLX 82), 150 for laboratory findings (LVFX 71, OFLX 79), and 141 for usefulness (LVFX 65, OFLX 76). There were no significant differences in the background factors of the patients between the two groups. 2) The overall clinical efficacy rates judged by the committee were 85.3% (58/68) for the LVFX group and 93.1% (67/72) for the OFLX group, and judged by the doctors in charge they were 85.3% (58/68) and OFLX 91.7% (66/72), respectively. There were no significant differences between the two groups. 3) The bacteriological eradication rates were 100% (21/21) in the LVFX group and 100% (33/33) in the OFLX group, without any significant difference between the two groups. 4) The incidences of side effects were 3.9% (3/76) in the LVFX group and 14.6% (12/82) in the OFLX group, and the difference between the two groups was statistically significant (P=0.03). The incidences of abnormal laboratory findings were 15.5% (11/71) in the LVFX group and 13.9% (11/79) in the OFLX group, and the difference between the two groups was not statistically significant. 5) The usefulness rates judged by the committee were 86.2% (56/65) for the LVFX group and 87.8% (65/76) for the OFLX group, and judged by the doctors in charge they were 87.7% (57/65) and 88.2% (67/76), respectively. There was no significant difference. The above results indicate that LVFX (100mg t. i. d) is as useful as OFLX (200mg t. i. d) in the treatment of patients with bacterial pneumonia.

Original languageEnglish
Pages (from-to)121-146
Number of pages26
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - 1992 May
Externally publishedYes

Keywords

  • DR-3355
  • Levofloxacin
  • Ofloxacin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint

Dive into the research topics of 'Comparative study of levofloxacin and ofloxacin in bacterial pneumonia by the double blind-method'. Together they form a unique fingerprint.

Cite this